Group 1 - The company, Fujian Guangshentang Pharmaceutical Co., Ltd., has received an inquiry letter from the Shenzhen Stock Exchange regarding its application for a private placement of shares [1][2] - The company has responded to the inquiry letter and updated its fundraising prospectus and related application documents [1] - The approval of the private placement is subject to review by the Shenzhen Stock Exchange and registration approval from the China Securities Regulatory Commission, with uncertainties regarding the outcome and timing [2] Group 2 - The company assures that the information disclosed is true, accurate, and complete, with no false records or misleading statements [1] - The company will fulfill its information disclosure obligations based on the progress of the private placement [2]

证券简称：广生堂 证券代码：300436 福建广生堂药业股份有限公司 （福建省宁德市柘荣县富源工业园区 1-7 幢） 2025 年度向特定对象发行 A 股股票 募集说明书 （申报稿） 保荐人（主承销商） 中国（上海）自由贸易试验区浦明路 8 号 二〇二五年七月 Fujian Cosunter Pharmaceutical Co., Ltd. 发行人声明 本公司及全体董事、监事、高级管理人员承诺募集说明书及其他信息披露 资料不存在任何虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性及 完整性承担相应的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财 务会计资料真实、完整。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行 人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与 之相反的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由 发行人自行负责，投资者自主判断发行人的投资价值，自主作出投资决策，自 行承担证券依法发行后因发行人经营与收益变 ...

股票简称：广生堂 股票代码：300436 关于福建广生堂药业股份有限公司 申请向特定对象发行股票的 二〇二五年七月 0 审核问询函的回复 保荐机构（主承销商） 中国（上海）自由贸易试验区浦明路 8 号 关于福建广生堂药业股份有限公司申请向特定对象发行股票的审核问询函的回复 深圳证券交易所： 一、如无特别说明，本回复报告中使用的简称或名称释义具有与《福建广生 堂药业股份有限公司 2025 年度向特定对象发行 A 股股票募集说明书》（以下简 称"募集说明书"）中相同的含义。 二、本回复报告中若出现总数与各分项数值之和尾数不符的情况，为四舍五 入原因造成。 三、本回复报告中的字体代表以下含义： | 黑体 | 问询函所列问题 | | --- | --- | | 宋体 | 对问询函所列问题的回复 | | 楷体（加粗） | 涉及修改或补充的内容 | 1 关于福建广生堂药业股份有限公司申请向特定对象发行股票的审核问询函的回复 问题 1： 1．根据申报材料，报告期内,发行人营业收入分别为 38,576.52 万元、 42,271.49 万元、44,145.77 万元和 9,760.80 万元，扣非后归母净利润分别为 -13, ...

国联民生证券承销保荐有限公司 关于 福建广生堂药业股份有限公司 2025 年度向特定对象发行 A 股股票 之 发行保荐书 保荐机构（主承销商） 2025 年 7 月 福建广生堂药业股份有限公司 2025 年度向特定对象发行 A 股股票发行保荐书 国联民生证券承销保荐有限公司 关于福建广生堂药业股份有限公司 2025年度向特定对象发行A股股票之发行保荐书 深圳证券交易所： 国联民生证券承销保荐有限公司（以下简称"国联民生承销保荐"、"保荐 机构"）接受福建广生堂药业股份有限公司（以下简称"广生堂"、"公司"或 "发行人"）的委托，担任广生堂本次向特定对象发行 A 股股票的保荐机构。 国联民生承销保荐及其保荐代表人根据《中华人民共和国公司法》（以下简称 "《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上市 公司证券发行注册管理办法》（以下简称"《注册管理办法》"）《证券发行上市 保荐业务管理办法》（以下简称"《保荐管理办法》"）等法律法规和中国证券 监督管理委员会（以下简称"中国证监会"）、深圳证券交易所（以下简称"深 交所"）的有关规定，诚实守信，勤勉尽责，严格按照依法制订的业务规则、行 业 ...

国浩律师（上海）事务所 关 于 福建广生堂药业股份有限公司 2025 年度向特定对象发行 A 股股票 之 补充法律意见书（一） 上海市山西北路 99 号苏河湾中心 25-28 层 邮编：200085 25-28/F, Suhe Centre, No.99 North Shanxi Road, Shanghai 200085, China 电话/Tel: +86 21 5234 1668 传真/Fax: +86 21 5243 1670 网址/Website: http://www.grandall.com.cn 国浩律师（上海）事务所 关于福建广生堂药业股份有限公司 2025 年度向特定对象发行 A 股股票 二〇二五年七月 | 第一节 | 声明事项 4 | | --- | --- | | 第二节 正 | 文 6 | | 第一部分 本次发行募集资金调整 | 6 | | 一、本次发行募集资金调减相关事宜 | 6 | | 第二部分 审核问询回复 | 6 | | 一、《审核问询函》之问题 1 | 7 | | 二、《审核问询函》之问题 2 | 60 | | 三、《审核问询函》之问题 3 | 85 | | 第三节 签署页 ...

国联民生证券承销保荐有限公司 关于 福建广生堂药业股份有限公司 2025 年度向特定对象发行 A 股股票 之 上市保荐书 保荐机构（主承销商） 2025 年 7 月 福建广生堂药业股份有限公司 2025 年度向特定对象发行 A 股股票上市保荐书 国联民生证券承销保荐有限公司 关于福建广生堂药业股份有限公司 2025年度向特定对象发行A股股票 之上市保荐书 深圳证券交易所： 国联民生证券承销保荐有限公司（以下简称"国联民生承销保荐"、"保荐 机构"）接受福建广生堂药业股份有限公司（以下简称"广生堂"、"公司"或 "发行人"）的委托，担任广生堂本次向特定对象发行 A 股股票的保荐机构。 国联民生承销保荐及其保荐代表人根据《中华人民共和国公司法》（以下简称"《公 司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上市公司 证券发行注册管理办法》（以下简称"《注册管理办法》"）《证券发行上市保 荐业务管理办法》（以下简称"《保荐管理办法》"）等法律法规和中国证券监 督管理委员会（以下简称"中国证监会"）、深圳证券交易所（以下简称"深交 所"）的有关规定，诚实守信，勤勉尽责，严格按照依法制订的业务规则、行业 ...

证券代码：300436 证券简称：广生堂 公告编号：2025051 公司本次向特定对象发行股票事项尚需通过深交所审核，并获得中国证券监 督管理委员会（以下简称"中国证监会"）同意注册后方可实施，最终能否通过 深交所审核并获得中国证监会作出同意注册的决定及其时间尚存在不确定性。公 司将根据该事项进展情况及时履行信息披露义务，敬请广大投资者谨慎决策，注 意投资风险。 福建广生堂药业股份有限公司 关于公司申请向特定对象发行股票的审核问询函回复及 募集说明书等申请文件更新的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 福建广生堂药业股份有限公司（以下简称"公司"）于 2025 年 6 月 13 日收 到深圳证券交易所（以下简称"深交所"）出具的《关于福建广生堂药业股份有 限公司申请向特定对象发行股票的审核问询函》（审核函〔2025〕020025 号）（以 下简称"问询函"），深交所发行上市审核机构对公司向特定对象发行股票的申请 文件进行了审核，并形成了审核问询问题。 公司按照问询函的要求，会同相关中介机构对问询函所列问题进行了认真研 究和落实，对问询函进 ...

关于福建广生堂药业股份有限公司 申请向特定对象发行股票的审核问询函有 关财务事项的说明 德皓函字[2025]00000097 号 北 京 德 皓 国 际 会 计 师 事 务 所 (特 殊 普 通 合 伙 ) Beijing Dehao International Certified Public Accountants (Limited Liability Partnership) 关于福建广生堂药业股份有限公司 申请向特定对象发行股票的审核问询函 有关财务事项的说明 目 录 页 次 一、 关于福建广生堂药业股份有限公司申请向特定对 象发行股票的审核问询函有关财务事项的说明 1-119 关 于 福 建 广 生 堂 药 业 股 份 有 限 公 司 申 请 向 特 定 对 象 发 行 股 票 的 审 核 问 询 函 有 关 财 务 事 项 的 说 明 德皓函字[2025]00000097号 深圳证券交易所： 由福建广生堂药业股份有限公司转来的深圳证券交易所《关于福建广生堂药业股份有限 公司申请向特定对象发行股票的审核问询函》（审核函〔2025〕020025 号，以下简称问询 函）奉悉。我们已对问询函中由会计师核查 ...

Core Insights - The innovative drug sector in both A-shares and Hong Kong stocks is experiencing strong performance, with significant gains in various companies such as Boteng Co., Changshan Pharmaceutical, and WuXi AppTec [1][2] - WuXi AppTec is expected to report a revenue of approximately 20.8 billion yuan for the first half of the year, marking a year-on-year growth of about 20.64%, with net profit expected to reach around 8.6 billion yuan, a year-on-year increase of approximately 101.92% [1] - The National Healthcare Security Administration has announced a plan for the adjustment of the national basic medical insurance drug catalog and the commercial health insurance innovative drug catalog for 2025, indicating a synchronized approach to drug catalog adjustments [1] Market Performance - The innovative drug ETF (515120) saw an increase of over 2%, marking its fourth consecutive day of gains, with a net inflow of 317 million yuan over the past ten trading days [2] - The Hong Kong innovative drug ETF (513120) also rose by over 1%, with a trading volume exceeding 4 billion yuan, making it the top-performing medical ETF in the market [2] - The leading medical ETF (560260) increased by over 2%, with major stocks like WuXi AppTec and Kelaiying leading the gains [2] Industry Trends - According to Guangfa Securities, China's innovative drug development is entering a phase of intensive policy benefits, with the number of original innovative drugs developed by Chinese companies expected to reach 3,575 by the end of 2024, surpassing the United States [2] - Global pharmaceutical giants are increasingly recognizing Chinese innovative drugs, with over 30% of collaborations involving upfront payments exceeding 50 million USD coming from China [2] - The focus should be on innovative drug companies with global competitiveness and the clinical value realization of their overseas products [2][3] Investment Opportunities - Aijian Securities highlights the trend of Chinese innovative drugs going global and maintains a bullish outlook on the medical technology sector for the year, emphasizing the importance of tracking ADCs and bispecific antibodies [3] - The upcoming mid-year report season presents opportunities to identify low-base, high-growth stocks, particularly in areas like medical devices, brain-computer interfaces, and AI in healthcare [3] Related Products - Innovative Drug ETF (515120) closely tracks the China Innovative Drug Industry Index, investing in companies involved in the research, production, and sales of innovative drugs [4] - Hong Kong Innovative Drug ETF (513120) tracks the Hong Kong Innovative Drug Index and supports T+0 trading, enhancing liquidity for investors [4] - Medical ETF Leader (560260) focuses on leading companies in the medical industry, including medical services and devices [4] - Pharmaceutical and Health ETF (159938) invests across various sectors in the pharmaceutical and healthcare industry [4]

Market Performance - The Shanghai Composite Index rose by 0.48% to 3509.68 points, while the Shenzhen Component Index increased by 0.47% to 10631.13 points, and the ChiNext Index gained 0.22% to 2189.58 points, with the SSE 50 Index up by 0.62% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 151.53 billion yuan, with sectors such as real estate, coal, brokerage, steel, pharmaceuticals, and banking showing significant gains [1] DDR4 Market Insights - The price of DDR4 continues to rise due to the exit of major players like Micron, Samsung, and SK Hynix from the market, with the DXI index reaching 83072.69 points, reflecting a year-to-date increase of 86.1% [2] - Demand for niche DRAM is expected to remain strong, driven by a weak recovery in smartphones, PCs, IoT, and industrial control sectors, alongside ongoing domestic replacement trends [2] Copper Price Volatility - Following Trump's consideration of a 50% tariff on imported copper, COMEX copper prices surged to nearly $5.9 per pound, closing at $5.51 per pound, marking a daily increase of nearly 10% [3] - The divergence in price movements between COMEX and LME copper indicates potential for increased volatility in copper prices in the short term, with expectations of a return to fundamental and macroeconomic influences [3] Photovoltaic Industry Developments - The price of silicon materials has surged to approximately 45,000 yuan per ton, a 25% increase, as the industry responds to "anti-involution" policies [4] - The rise in silicon prices is expected to lead to price increases across the photovoltaic supply chain, including N-type silicon wafers and potentially batteries and components [4] Banking Sector Stability - The banking sector's foundation for "stable returns" has been strengthened, supported by macroeconomic and regulatory policies that enhance profitability stability [6] - The focus on low-valuation stocks and beta varieties is expected to continue, with institutional investors showing increased interest in stable return assets [6] Strategic Mineral Export Control - The Ministry of Commerce has initiated a special action to combat the smuggling and export of strategic minerals, including antimony and gallium, to prevent illegal outflows [8] Innovative Drug Developments - Guangshengtang's innovative drug GST-HG131 for hepatitis B treatment has been included in the list of breakthrough therapy products, indicating significant clinical advantages [9] Rare Earth Pricing Adjustments - Baotou Steel's announcement to adjust the price of rare earth concentrates to 19,109 yuan per ton (excluding tax) reflects ongoing changes in the pricing mechanism for rare earth products [10]